Literature DB >> 25202050

Requirement of JNK signaling for self-renewal and tumor-initiating capacity of ovarian cancer stem cells.

Manabu Seino1, Masashi Okada2, Keita Shibuya3, Shizuka Seino4, Shuhei Suzuki5, Tsuyoshi Ohta6, Hirohisa Kurachi7, Chifumi Kitanaka8.   

Abstract

BACKGROUND/AIM: Activation of the c-JUN N-terminal kinase (JNK) signaling pathway has been associated with poor survival of ovarian cancer patients, but the role(s) and significance of JNK signaling in ovarian cancer cells remain poorly understood. In the present study, we aimed to investigate the role of JNK specifically in ovarian cancer stem cells (CSCs).
MATERIALS AND METHODS: The effect of JNK inhibition on the self-renewal (CSC marker expression, sphere-forming ability) and tumor-initiating capacity was examined in CSCs derived from the A2780 human ovarian cancer cell line. JNK inhibition was achieved either pharmacologically or genetically by use of RNA interference.
RESULTS: Both pharmacological and genetic targeting of JNK resulted in loss of self-renewal and tumor-initiating capacity of A2780 CSCs.
CONCLUSION: Our findings demonstrate, to our knowledge for the first time, that JNK has a pivotal role in the maintenance of ovarian CSCs. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Ovarian cancer; cancer initiating cells; tumorigenicity; xenograft analysis

Mesh:

Substances:

Year:  2014        PMID: 25202050

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells.

Authors:  Keita Shibuya; Masashi Okada; Shuhei Suzuki; Manabu Seino; Shizuka Seino; Hiroyuki Takeda; Chifumi Kitanaka
Journal:  Oncotarget       Date:  2015-01-20

Review 2.  The Jun N-terminal kinases signaling pathway plays a "seesaw" role in ovarian carcinoma: a molecular aspect.

Authors:  Yingyu Dou; Xiaoyan Jiang; Hui Xie; Junyu He; Songshu Xiao
Journal:  J Ovarian Res       Date:  2019-10-21       Impact factor: 4.234

3.  Identification of Key Pathways and Genes in the Orai2 Mediated Classical and Mesenchymal Subtype of Glioblastoma by Bioinformatic Analyses.

Authors:  Feng Yuan; Li Yi; Long Hai; Yingshuai Wang; Yihan Yang; Tao Li; Luqing Tong; Haiwen Ma; Peidong Liu; Haolang Ming; Bingcheng Ren; Shengping Yu; Yu Lin; Xuejun Yang
Journal:  Dis Markers       Date:  2019-10-20       Impact factor: 3.434

Review 4.  JNK in Tumor Microenvironment: Present Findings and Challenges in Clinical Translation.

Authors:  Shing Yau Tam; Helen Ka-Wai Law
Journal:  Cancers (Basel)       Date:  2021-05-03       Impact factor: 6.639

5.  The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo.

Authors:  Masashi Okada; Kenta Kuramoto; Hiroyuki Takeda; Hikaru Watarai; Hirotsugu Sakaki; Shizuka Seino; Manabu Seino; Shuhei Suzuki; Chifumi Kitanaka
Journal:  Oncotarget       Date:  2016-05-10

6.  Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson's disease, as an anti-cancer stem cell drug.

Authors:  Masashi Okada; Hiroyuki Takeda; Hirotsugu Sakaki; Kenta Kuramoto; Shuhei Suzuki; Tomomi Sanomachi; Keita Togashi; Shizuka Seino; Chifumi Kitanaka
Journal:  Oncotarget       Date:  2017-10-24

7.  Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer.

Authors:  Ji Hee Ha; Mingda Yan; Rohini Gomathinayagam; Muralidharan Jayaraman; Sanam Husain; Jinsong Liu; Priyabrata Mukherjee; E Premkumar Reddy; Yong Sang Song; Danny N Dhanasekaran
Journal:  Oncotarget       Date:  2016-11-08

Review 8.  JNK Signaling in Stem Cell Self-Renewal and Differentiation.

Authors:  Takashi Semba; Rachel Sammons; Xiaoping Wang; Xuemei Xie; Kevin N Dalby; Naoto T Ueno
Journal:  Int J Mol Sci       Date:  2020-04-09       Impact factor: 5.923

9.  Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1-JNK axis.

Authors:  Shuhei Suzuki; Masashi Okada; Tomomi Sanomachi; Keita Togashi; Shizuka Seino; Atsushi Sato; Masahiro Yamamoto; Chifumi Kitanaka
Journal:  J Biol Chem       Date:  2020-10-28       Impact factor: 5.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.